When was SuperX founded?

SuperX was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is SuperX located?

SuperX is headquartered in Cambridge, United Kingdom.

How many employees does SuperX have?

As of Sep 30, 2018, the latest employee count at SuperX is 2.

Is SuperX a funded company?

SuperX is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Feb 16, 2017.

How much is SuperX worth?

The latest valuation of SuperX is $***** as of Jan 07, 2016.

When was the latest funding round of SuperX?

SuperX's latest funding was a $***** Series A round on Feb 16, 2017, with participation from 2 investors. Its primary sector is Immunotherapy. In United Kingdom, the Immunotherapy sector has seen $212M in funding in 2026 to date.

Where does SuperX rank among its competitors?

SuperX ranks 1871st amongst 2666 active competitors, of which 900 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of SuperX?

SuperX's top competitors include Jazz Pharmaceuticals, argenx and Alexion. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

SuperX - 2026 Company Profile, Team, Funding & Competitors

Company Details

SuperX is a UK-based, early-stage, funded, virtual biotech developing anticoagulation therapeutics without risk of bleeding. It is a single-asset company. The company is working on the discovery of antibodies against an undisclosed target in the blood coagulation cascade. The company is incubated at the t Babraham Research Campus, in Cambridge UK.

Website: superxpharma.com
Social

Key Metrics

Founded Year

2016

Location

Cambridge, United Kingdom

Stage

Series A

Total Funding

$11M in 1 round

Latest Funding Round

Series A, Feb 16, 2017, $*****

Post Money Valuation

$***** as on Jan 07, 2016

Investors

Medicxi & 2 more

Ranked

1871^st among 2666 active competitors

Employee Count

2 as on Sep 30, 2018

Similar Companies

argenx & 316 more

View SuperX's full profile

SuperX has raised a total funding of $11M over 1 round. Its latest funding round was a Series A round on Feb 16, 2017 for $*****. 2 investors participated in its latest round. SuperX has 3 institutional investors.

Here is the list of recent funding rounds of SuperX:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 16, 2017	2910329	Series A	1145170	6504515	9935434	4578016

Access funding benchmarks and valuations. Sign up today!

View details of SuperX's funding rounds and investors

SuperX's Board of Directors

SuperX's board has 6 active members. Kevin Johnson, Giovanni Mariggi, Jeanne Bolger, Maciej Drozdz, Trevor Baglin and James Huntington are part of team.

Here is the list of SuperX's board of directors:

Name	Type	Representing	Status	Duration
Trevor Baglin	Team	-	Current	10y 10m
James Huntington	Team	-	Current	10y 10m
thictrs	Team	-	Past	8y 9m
Kevin Johnson	Investor	Medicxi	Current	10y 8m
Giovanni Mariggi	Investor	Medicxi	Current	9y 9m
egladak	Investor	okcmsyw	Current	2y 8m
nfpasqp	Investor	jtkimat	Current	5y 9m
o{kwwxc	Investor	ykjxlos	Past	8y 5m
erxsycd	Investor	tbewvls	Past	2y 4m

SuperX's employee count trend

SuperX has 2 employees as of Sep 18. Here is SuperX's employee count trend over the years:

Uncover SuperX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SuperX include Jazz Pharmaceuticals, argenx and Alexion. Here is the list of Top 10 competitors of SuperX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
1871st	SuperX 2016, Cambridge (United Kingdom), Series A	UK-based, early-stage, funded biotech developing anticoagulation therapeutics without risk of bleeding	$11M	Johnson & Johnson Innovation – JJDC, Medicxi ... & 1 others	26/100